410 related articles for article (PubMed ID: 23253379)
1. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
2. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
3. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
5. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
6. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
10. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
11. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
12. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Zhang X; Jin FS; Zhang LG; Chen RX; Zhao JH; Wang YN; Wang EF; Jiang ZD
Asian Pac J Cancer Prev; 2013; 14(7):4261-5. PubMed ID: 23991987
[TBL] [Abstract][Full Text] [Related]
15. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
[TBL] [Abstract][Full Text] [Related]
17. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
18. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; Mackey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW;
J Natl Cancer Inst; 2014 Jan; 106(1):djt347. PubMed ID: 24301456
[TBL] [Abstract][Full Text] [Related]
20. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
Jordheim LP; Dumontet C
Biomark Med; 2013 Aug; 7(4):663-71. PubMed ID: 23905902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]